Stage IIIC Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Dabrafenib (DB08912)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02196181Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryTreatment